CALC — CalciMedica, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1534133 ·
Last close
$0.93
Market Cap
$14.69M
52W High
$1.15
52W Low
$0.53
ADV30
2,454,079
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -5,611,000 | 4,976,000 | 8,609,000 | 8,164,000 | 9,713,000 |
| Dec 2025 | 0 | — | -4,385,000 | -10,760,000 | 13,591,000 | 11,520,000 | 20,232,000 |
| Sep 2025 | 0 | — | -5,618,000 | -7,804,000 | 14,913,000 | 5,470,000 | 15,181,000 |
| Jun 2025 | 0 | — | -6,621,000 | -5,956,000 | 19,080,000 | 5,918,000 | 12,977,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-21,156,000
Investing CF
$12,294,000
Financing CF
$4,470,000
CapEx
$-28,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.98
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-184,350,000
Inventory
—
Receivables
—
ST Investments
$0
EBIT TTM
$-18,250,000
Pretax Income TTM
$-19,544,000
Interest Exp TTM
$1,294,000
Analysts
3
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -23,121,000 | -29,562,000 | 13,591,000 | 20,232,000 | — | -21,178,000 |
| Dec 2024 | 0 | -24,204,000 | -13,700,000 | 19,794,000 | 5,384,000 | — | -21,146,000 |
| Dec 2023 | 0 | -38,075,000 | -34,357,000 | 12,185,000 | 4,028,000 | — | -25,730,000 |
| Dec 2022 | 0 | -14,193,000 | -7,824,000 | 3,349,000 | 12,582,000 | — | -11,757,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.63
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| SCNX | Scienture Holdings, Inc. | $15.04M | $0.37 | — |
| GTBP | GT Biopharma, Inc. | $15.33M | $0.43 | — |
| BFRI | Biofrontera Inc. | $14.08M | $1.10 | — |
| COCP | Cocrystal Pharma, Inc. | $13.93M | $1.01 | — |
| TPST | Tempest Therapeutics, Inc. | $15.55M | $0.97 | — |
News headlines (Yahoo Finance, 1h cache)
CalciMedica Announces Private Placement Financing for Up to Approximately $49 Million to Advance Pulmonary Hypertension Program
2026-06-24 11:01 · Yahoo
CalciMedica Announces Clinical Development of Auxora May Proceed Following FDA Review of KOURAGE Trial Interim Safety Data
2026-06-24 11:00 · Yahoo
CalciMedica Reports First Quarter 2026 Financial Results and Provides Clinical & Corporate Updates
2026-05-12 11:00 · Yahoo
CalciMedica Reports 2025 Financial Results and Provides Clinical Updates
2026-03-03 12:00 · Yahoo
CalciMedica’s stock drops 75% on acute kidney injury trial termination
2026-01-29 12:24 · Yahoo
CalciMedica Announces Discontinuation of Phase 2 KOURAGE Trial in AKI Following Independent Data Monitoring Committee Recommendation
2026-01-28 12:00 · Yahoo
CalciMedica Reports Third Quarter 2025 Financial Results and Provides Clinical & Corporate Updates
2025-11-12 12:01 · Yahoo
CalciMedica Announces Publication in JCI Insight of Preclinical Data Supporting CRAC Channel Inhibitor as a Potential Therapy for Pulmonary Arterial Hypertension
2025-11-12 12:00 · Yahoo
CalciMedica Presents Data from Preclinical Study of Auxora™ in an Animal Model of AKI at ASN Kidney Week 2025
2025-11-10 12:00 · Yahoo
CalciMedica and Telperian Announce Collaboration to Integrate Innovative Artificial Intelligence Engine to Analysis of Clinical Trials of Auxora™
2025-10-14 11:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.